argenx OKd on Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

  argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA^® (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous (SC) use for the treatment of adult patients with generalized myasthenia gravis (gMG), who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs). Following this decision, VYVGART is now approved in Japan for both intravenous (IV) and self-administered SC use.

https://www.biospace.com/article/releases/argenx-announces-approval-of-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-injection-for-subcutaneous-use-in-japan-for-generalized-myasthenia-gravis-/